British pharmaceutical giant GlaxoSmithKline (GSK) announced Monday that it is creating a new company for research, development and commercialization of “bioelectronic” medicines in partnership with Alphabet Inc.’s life sciences unit, Verily Life Sciences. The two companies plan to invest 540 million pounds ($714 million) over the next seven years in the new entity, named Galvani Bioelectronics.
